[go: up one dir, main page]

SV2002000442A - METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN REF. MSB-7266-SV - Google Patents

METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN REF. MSB-7266-SV

Info

Publication number
SV2002000442A
SV2002000442A SV2001000442A SV2001000442A SV2002000442A SV 2002000442 A SV2002000442 A SV 2002000442A SV 2001000442 A SV2001000442 A SV 2001000442A SV 2001000442 A SV2001000442 A SV 2001000442A SV 2002000442 A SV2002000442 A SV 2002000442A
Authority
SV
El Salvador
Prior art keywords
ryk
msb
regulating angiogenesis
association
protein ref
Prior art date
Application number
SV2001000442A
Other languages
Spanish (es)
Inventor
Steve Roczniak
Nathalie A Dubois-Stringfellow
Alya Zolotorev
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of SV2002000442A publication Critical patent/SV2002000442A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE ENCONTRO QUE LA PROTEINA RYK TENIA UNA NOVEDOSA ACTIVIDAD EN LA REGULACION DE LA ANGIOGENESIS. SE CONSTRUYERON NUEVAS PROTEINAS RYK VARIANTES QUE SON VENTAJOSAS PARA MODULAR LA ACTIVIDAD FORMADORA DE CAPILARES DE LAS CELULAS ENDOTELIALES. LAS PROTEINAS RYK VARIANTES PUEDEN SER UTILIZADOS COMO AGENTES TERAPEUTICOS EN ENFERMEDADES TALES COMO EL CANCER, LA CICATRIZACION DE HERIDAS, LAS RETINOPATIAS DIABETICAS, LA DEGENERACION MACULAR Y LAS ENFERMEDADES CARDIOVASCULARES, ASI COMO OTRAS ENFERMEDADES O TRASTORNOS CICLICOS EN LA QUE LA ANGIOGENESIS ESTA INVOLUCRADA EN LA CAUSA O EL TRATAMIENTO DE LA ENFERMEDADI FOUND THAT THE RYK PROTEIN HAD A NEW ACTIVITY IN THE REGULATION OF ANGIOGENESIS. NEW RYK VARIANTS PROTEINS WHICH ARE ADVANTAGE TO MODULATE THE CAPILLARY FORMING ACTIVITY OF ENDOTELIAL CELLS WERE BUILT. RYK VARIANTS PROTEINS CAN BE USED AS THERAPEUTIC AGENTS IN SUCH DISEASES AS CANCER, WOUND HEALING, DIABETIC RETINOPATHICS, MACULAR DEGENERATION AND CARDIOVASTIC ASSOCIATION IN OCCUPATIONAL ASSOCIATION IN OCCUPATIONAL DISEASE CAUSE OR TREATMENT OF THE DISEASE

SV2001000442A 2000-05-10 2001-05-09 METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN REF. MSB-7266-SV SV2002000442A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
SV2002000442A true SV2002000442A (en) 2002-07-03

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000442A SV2002000442A (en) 2000-05-10 2001-05-09 METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN REF. MSB-7266-SV

Country Status (13)

Country Link
EP (1) EP1287121A2 (en)
JP (1) JP2004527206A (en)
AR (1) AR028424A1 (en)
AU (1) AU2001261343A1 (en)
CA (1) CA2408349A1 (en)
CO (1) CO5300464A1 (en)
DO (1) DOP2001000164A (en)
EC (1) ECSP014068A (en)
GT (1) GT200100079A (en)
PE (1) PE20011218A1 (en)
SV (1) SV2002000442A (en)
UY (1) UY26696A1 (en)
WO (1) WO2001085789A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003206854A1 (en) * 2002-02-06 2003-09-02 Developgen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Kinases involved in the regulation of energy homeostasis
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition including Afflipersept, Folinic Acid, 5- Fluorouracil (5- Fu) and Irenosetan (FOLFIRI)
SI3170005T1 (en) 2014-07-18 2019-08-30 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
CN117979997A (en) * 2021-08-18 2024-05-03 加利福尼亚大学董事会 Anti-receptor-associated tyrosine kinase (RYK) antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0646129A4 (en) * 1992-05-11 1995-07-19 Ludwig Inst Cancer Res RECEPTOR-TYPE TYROSINE KINASE-LIKE MOLECULES.
WO1996020403A1 (en) * 1994-12-23 1996-07-04 Ludwig Institute For Cancer Research Assay, receptor proteins and ligands
AU4278299A (en) * 1998-06-11 1999-12-30 Astrazeneca Ab Human receptor tyrosine kinase
EP1126869B1 (en) * 1998-10-28 2008-09-03 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using the trk receptor ligands bdnf, nt-3 and nt-4

Also Published As

Publication number Publication date
EP1287121A2 (en) 2003-03-05
WO2001085789A3 (en) 2002-05-16
ECSP014068A (en) 2002-02-25
CO5300464A1 (en) 2003-07-31
AR028424A1 (en) 2003-05-07
JP2004527206A (en) 2004-09-09
CA2408349A1 (en) 2001-11-15
AU2001261343A1 (en) 2001-11-20
GT200100079A (en) 2001-12-31
PE20011218A1 (en) 2002-02-01
DOP2001000164A (en) 2002-05-15
UY26696A1 (en) 2001-12-28
WO2001085789A2 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
ATE340581T1 (en) METHOD FOR TREATING PROSTATE DISEASES USING DELAYED AND/OR EXTENDED RELEASE VITAMIN D FORMULATIONS
SV1995000007A (en) DERIVATIVES OF 5-SUBSTITUTED MYCOPHENOLIC ACID.
ES2166783T3 (en) ACTIVATED FACTOR VIII USED AS A THERAPEUTIC AGENT AND METHOD FOR THE TREATMENT OF FACTOR DEFICIENCY VIII.
CO4830493A1 (en) ANTIBODIES AGAINST HUMAN CD40
CY1107248T1 (en) SUSPENED PROTEINS
NO962088D0 (en) Preparation for in vivo production of therapeutic products
ECSP045065A (en) QUERATINOCITS USED AS A BIOLOGICALLY ACTIVE SUBSTANCE IN WOUND TREATMENT
IS4083A (en) Composition of pharmaceutical substances, method of manufacture thereof, and use as pharmaceuticals
ATE466592T1 (en) USE OF GLP-2 IN CONJUNCTION WITH ANOTHER THERAPEUTIC AGENT IN BONE DISEASES
BR0204596A (en) Topical composition, and methods for improving the aesthetic appearance of the skin, for enhancing the therapeutic efficacy of a topical composition for the skin, nail, lips and / or hair, and for enhancing the production of a predetermined plant cell constituent.
ATE365550T1 (en) USE OF A PROTEIN KINASE INHIBITOR SUCH AS GENISTEIN IN THE TREATMENT OF DIABETIC RETINOPATHY
BRPI0407611A (en) anti-cancer agent comprising protein lk8 as an active ingredient
SV2002000442A (en) METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN REF. MSB-7266-SV
PT1343472E (en) TIXOTROPIC NASAL SPRAY
HRP20041095B1 (en) USE OF CONCENTRATED MARE'S MILK DRYED ON A BIOLOGICALLY INERTIVE, HIGHLY DISPERSED MATRIX
ES2110057T3 (en) MEDICINAL COMPOSITION CONTAINING TCF-II.
ATE283058T1 (en) USE OF A COMPOUND CONTAINING POLLEN EXTRACT TO TREAT DYSPHORIA
CY1107346T1 (en) PHARMACEUTICAL COMPOSITION FOR INTERCELLARIC ACIDISE WITH CIS-URACANIC ACID
SV2002000362A (en) PROTEINS THAT HAVE AN ANGIOGENESIS MODULATING ACTIVITY REF.MSB-7265-SV
CO5070621A1 (en) METHOD FOR INCREASING THE OSEO VOLUME
IT1320192B1 (en) THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PSORIASIS.
DOP2001000141A (en) PROTEIN ACTING AS AN ANGIOGENIC MODULATOR
ATE374048T1 (en) USE OF MATRIX PROTEIN FOR CONTROLLED TISSUE REGENERATIONS
DE69821227D1 (en) USE OF PAPOVAVIRUS CAPSIDE PROTEINS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS IN NERV CELLS
AR034063A1 (en) CAPILLARY PRODUCTS AND USE OF NATURAL OILS WITH TOCOPHEROLS, STEROLS AND / OR CAROTENOIDS AND PREPARATIONS

Legal Events

Date Code Title Description
FD Lapse